Sunday, February 23, 2020

Sunday, February 23, 2020

U.S. FOOD AND DRUG ADMINISTRATION: Overview of FDA’s Perinatal Health Center of Excellence: Development and Validation of Predictive Systems

U.S. Food and Drug Administration recently issued the following announcement. 

Date: July 11, 2019Time:July 11, 2019

12:00 PM EDT – 01:00 PM EDT

Registration: https://collaboration.fda.gov/reg71119/event/registration.html

Organized By: Office of the Chief Scientist

For technical assistance: Please contact Jeffery Rexrode at: Jeffery.Rexrode@fda.hhs.gov

or Devin Thomas at: Devin.Thomas@fda.hhs.gov

Remote Access Instructions are found at bottom of web page*

Presented by: 

Amy Inselman, PhD

Division of Systems Biology

Biomarkers and Alternative Models Branch

FDA’s National Center for Toxicological Research (NCTR)

CE Credit Available

Webcast Lecture: 

Overview of FDA’s Perinatal Health Center of Excellence: Development and Validation of Predictive Systems

About the Presentation:

FDA has recognized the need for coordinated research to address public health needs during the perinatal period.  These include the health of the mother, premature infants, and newborns as well as development throughout childhood. To that end, FDA’s National Center for Toxicological Research (NCTR) established FDA’s virtual Perinatal Health Center of Excellence (PHCE) to address the special public health needs of these important and understudied populations.  For example, many FDA-regulated products given to newborns and infants — or provided to pregnant mothers — haven’t been studied extensively in such populations.  This has left knowledge gaps about their safety, efficacy, or potential toxicity. Environmental exposure through foods and pre-existing conditions are another area where vast knowledge gaps exist. Infants consume more food per kilogram of body weight than any other age group, resulting in the potential for higher dietary exposures to chemicals.

To tackle these regulatory science issues facing FDA, studies will be planned and conducted across the agency’s product centers.  PHCE-funded research includes in silico models, stem cell systems and other in vitro models, laboratory animal studies, translational and clinical studies, mathematical modeling, bioanalytical chemistry, exposure science, and bioinformatics targeting the perinatal period.  This presentation will highlight a PHCE-funded project to investigate opioid-induced neural tube defects in a mouse model. This project seeks to clarify the link between maternal toxicity and embryo-fetal development following opioid exposure.  The results may improve health communications (i.e. label change) that would help pregnant women and healthcare practitioners make more informed decisions about the risk of opioid exposure during early development.

About the Presenter

Dr. Amy Inselman is a staff fellow in NCTR’s Division of Systems Biology, Biomarkers and Alternative Models Branch. Dr. Inselman earned her PhD from the University of Tennessee, where she focused on elucidation of the key proteins involved in regulating the meiotic G2/MI division of mouse spermatocytes.  Following completion of her PhD, Dr. Inselman was awarded an Intramural Research Training Award to complete her postdoctoral training at the National Institute for Environmental Health Sciences in the Laboratory of Developmental and Reproductive Toxicology, Gamete Biology section. In 2009, Dr. Inselman joined FDA as an ORISE fellow at NCTR. In 2012, she became a member of the Division of Systems Biology, Biomarkers and Alternative Models Branch.  Dr. Inselman has worked with various FDA product centers investigating the developmental and reproductive toxicity of regulated products, using both in vivo and in vitro test systems. 

Remote Access Instructions/Webcast Registration: (Pre-registration is required): To register for the webcast, please click the link and then follow the instructions on the registration pages. After you register you will receive links via e-mail as outlook calendar invitations with information on how to access the live webinars. You must log in with your username and password which you create when you register. You must pre-register at least one day before the event to ensure that the access link e-mails and outlook invitations are received for each day.

HHS/LMS Registration Link for FDA employees for in-person attendance is here. (FDA employees must also register in the LMS if registered for the webcast to ensure that the training will be listed on their official LMS transcripts after completing it). 

Registrants watching the live Grand Rounds webcasts should be able to:

  1. See streaming video of the presenter
  2. See streaming slides of the presentation
  3. Hear the speaker’s audio through their computer or smartphone/tablet speakers
  4. Be able to type questions into a Q/A window 
  5. See streaming closed captioning
When registering in Adobe Connect in advance, review the Quick Start Guide for Participants before logging in to make sure that you know how to best use the system.

To test your system's connection before logging in to an Adobe Connect meeting visit here.

Event Materials

  • July 11 FDA Grand Rounds CE Credit Activity Outline (161.39 KB)
Original source can be found here.

Organizations in this Story

U.S. Food and Drug Administration

More News

FDA Reporter